SOPHiA GENETICS SA (SOPH)
- Business Wire
Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
BOSTON & LAUSANNE, Switzerland, March 28, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment.
- Simply Wall St.
SOPHiA GENETICS SA (NASDAQ:SOPH) surges 23%; individual investors who own 44% shares profited along with institutions
Key Insights The considerable ownership by individual investors in SOPHiA GENETICS indicates that they collectively...
- Zacks
SOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?
SOPHiA GENETICS SA (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
